Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer

Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer

Purpose: Guidelines for locally advanced non-small cell lung cancer (LA-NSCLC) recommend definitive chemoradiation therapy (CRT) for cN2-N3 disease, reserving surgery for patients with minimal nodal involvement at presentation. The current literature suggests that surgery after CRT for stage III NSC...

Full description

Bibliographic Details
Main Authors: Melissa A.L. Vyfhuis, MD PhD, Neha Bhooshan, MD PhD, Whitney M. Burrows, MD, Michelle Turner, NP, Mohan Suntharalingam, MD MBA, James Donahue, MD, Elizabeth M. Nichols, MD, Josephine Feliciano, MD, Søren M. Bentzen, PhD DMSc, Shahed Badiyan, MD, Shamus R. Carr, MD, Joseph Friedberg, MD, Charles B. Simone, II, MD, Martin J. Edelman, MD, Steven J. Feigenberg, MD, Pranshu Mohindra, MD
Format: Article
Language:English
Published: Elsevier 2017-07-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109417301148

Internet

http://www.sciencedirect.com/science/article/pii/S2452109417301148

Similar Items